Incidentally Diagnosed Simultaneous Second Primary Tumor of the Sphenoid Sinus in a Patient With Lung Cancer

2009 ◽  
Vol 20 (6) ◽  
pp. 2175-2177
Author(s):  
Ozgur Yigit ◽  
Umit Taskin ◽  
Ahmet Demir ◽  
Kemal Behzatoglu
Keyword(s):  
Lung Cancer ◽  
Primary Tumor ◽  
Sphenoid Sinus ◽  
Second Primary ◽  
Second Primary Tumor

scholarly journals Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database

2021 ◽  
Author(s):  
Congcong Chen ◽  
Zixiang Wu ◽  
Ziheng Wu ◽  
Chuanqiang Wu ◽  
Qi Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Primary Tumor ◽  
Early Stage ◽  
Second Primary ◽  
Term Survival ◽  
Long Term Survival ◽  
Therapeutic Method ◽  
Second Primary Tumor ◽  
Disease Free

Abstract Background Early-stage non-small lung cancer patients may survive long enough to develop second primary lung cancers. However, few studies have accurately described the therapeutic method, evaluation or prognostic factors for long-term survival in this complex clinical scenario.Methods Patients who had first and second primary non-small lung cancer in the Surveillance, Epidemiology, and End Results database between 2004 and 2015 were evaluated. The patients were included when their tumors were pathologically diagnosed as non-small lung cancer and in the early-stage (less than 3 cm and with no lymph node metastasis). Therapeutic methods were categorized as lobectomy, sublobectomy or no surgery. The influence of different therapeutic methods on the overall survival rate was compared. Results For the first primary tumor, patients who underwent lobectomy achieved superior survival benefits compared with patients who underwent sublobectomy. For the second primary tumor, long-term survival was similar in patients who underwent lobectomy and those who underwent sublobectomy treatment. The multivariate analysis indicated that age, disease-free time interval, sex, first and second type of surgery were independent prognostic factors for long-term survival. Our results showed that the 5-year overall survival rate was 91.9% when the disease-free interval exceeded 24 months.Conclusion Lobectomy for the first primary tumor followed by sublobectomy for the second primary tumor may be a beneficial therapeutic method for patients. If the disease-free interval exceeds 24 months, the second primary tumor will have no influence on the natural course for patients diagnosed with a first primary non-small lung cancer.

scholarly journals Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Congcong Chen ◽  
Zixiang Wu ◽  
Ziheng Wu ◽  
Chuanqiang Wu ◽  
Qi Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Primary Tumor ◽  
Early Stage ◽  
Second Primary ◽  
Term Survival ◽  
Long Term Survival ◽  
Therapeutic Method ◽  
Second Primary Tumor ◽  
Disease Free

Abstract Background Early-stage non-small lung cancer patients may survive long enough to develop second primary lung cancers. However, few studies have accurately described the therapeutic method, evaluation or prognostic factors for long-term survival in this complex clinical scenario. Methods Patients who had first and second primary non-small lung cancer in the Surveillance, Epidemiology, and End Results database between 2004 and 2015 were evaluated. Patients were included when their tumors were pathologically diagnosed as non-small lung cancer and in the early-stage (less than 3 cm and with no lymph node metastasis). Therapeutic methods were categorized as lobectomy, sublobectomy or no surgery. The influence of different therapeutic methods on the overall survival rate was compared. Results For the first primary tumor, patients who underwent lobectomy achieved superior survival benefits compared with patients who underwent sublobectomy. For the second primary tumor, long-term survival was similar in patients who underwent lobectomy and those who underwent sublobectomy treatment. The multivariate analysis indicated that age, disease-free time interval, sex, and first and second types of surgery were independent prognostic factors for long-term survival. Our results showed that the 5-year overall survival rate was 91.9% when the disease-free interval exceeded 24 months. Conclusion Lobectomy for the first primary tumor followed by sublobectomy for the second primary tumor may be a beneficial therapeutic method for patients. If the disease-free interval exceeds 24 months, the second primary tumor will have no influence on the natural course for patients diagnosed with a first primary non-small lung cancer.

PO-0969 Evaluation of the use of reirradiation in head and neck recurrent cancer or second primary tumor.

2021 ◽  
Vol 161 ◽  
pp. S803-S804
Author(s):  
L. Gutiérrez Bayard ◽  
M.C. Salas Buzón ◽  
R. Rodriguez Sanchez
Keyword(s):  
Head And Neck ◽  
Primary Tumor ◽  
Second Primary ◽  
Recurrent Cancer ◽  
Second Primary Tumor

PATIENT WITH SQUAMOUS CELL CARCINOMA AND SECOND PRIMARY TUMOR ON THE LIPS: A CASE REPORT

2020 ◽  
Vol 130 (3) ◽  
pp. e144
Author(s):  
ANTONIA TAIANE LOPES DE MORAES ◽  
YASMIM RODRIGUES SENA ◽  
KAROLYNY MARTINS BALBINOT ◽  
BEATRIZ VOSS MARTINS ◽  
SÂMIA CORDOVIL DE ALMEIDA
Keyword(s):  
Squamous Cell Carcinoma ◽  
Case Report ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Primary Tumor ◽  
Second Primary ◽  
Second Primary Tumor

Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results.

1996 ◽  
Vol 14 (8) ◽  
pp. 2331-2336 ◽  
Author(s):  
O Laccourreye ◽  
D Brasnu ◽  
V Bassot ◽  
M Ménard ◽  
D Khayat ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Local Recurrence ◽  
Cell Carcinoma ◽  
Local Control ◽  
Squamous Cell ◽  
Distant Metastasis ◽  
Primary Tumor ◽  
Second Primary ◽  
Nodal Recurrence ◽  
Second Primary Tumor

PURPOSE To evaluate cisplatin-fluorouracil exclusive chemotherapy (EC) for T1-T3N0 glottic squamous cell carcinoma complete clinical responders (CCR) after cisplatin-fluorouracil induction chemotherapy (IC). PATIENTS AND METHODS A retrospective analysis was performed of 58 patients with T1-T3N0 glottic squamous cell carcinoma CCR after IC consecutively managed at our department between 1985 and 1992. Twenty-one CCR were managed with EC. Thirty-seven CCR were managed with IC and a conventional laryngeal-preservation modality. Analyses of survival, local control, nodal recurrence, distant metastasis, and metachronous second primary tumor were performed using the Kaplan-Meier actuarial life-table method. In CCR managed with EC, the independent factors of age, tumor classification, exact tumor location, true vocal cord motion, arytenoid cartilage motion, total dosage of drugs delivered, and number of courses received were tested for potential correlation with survival, local recurrence, nodal recurence, and distant metastasis. RESULTS The 5-year survival, local control, nodal recurrence, distant metastasis, and metachronous second primary tumor rates in CCR managed with EC were 95.2%, 70.7%, 0%, 0%, and 14.3%, respectively. The 5-year rates of survival, local control, nodal recurrence, distant metastasis, and metachronous second primary tumor in CCR managed with IC and a conventional laryngeal-preservation modality were 86.1%, 97%, 2.7%, 6%, and 14.5%, respectively. Local recurrence was statistically more likely in CCR managed with EC (P = .002). Local recurrence in CCR managed with EC was always salvaged with partial laryngectomy or radiation therapy, which resulted in an overall 100% local control and laryngeal-preservation rate within this group. In CCR managed with EC, none of the variables analyzed was statistically related to survival, local recurrence, nodal recurrence, or distant metastasis. CONCLUSION The present retrospective studies demonstrated that within T1-T3N0 glottic squamous cell carcinoma CCR, there is clearly a significant subset of patients with chemocurable tumors who achieved both perfect preservation of structure-supporting voice and long-term survival after EC. Careful monthly follow-up evaluation allowed for timely successful salvage of local recurrence after EC without the need for total laryngectomy. Such management did not appear to increase the risk for subsequent nodal failure, subsequent distant metastasis, or reduced survival.

Clinical and pathologic characteristics of patients with breast cancer and a second non-breast primary tumor.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11539-e11539
Author(s):  
Gul Atalay Basaran ◽  
Aziz Yazar ◽  
Cihan Uras ◽  
Evrim Tezcanli ◽  
Devrim Cabuk ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Primary Tumor ◽  
Breast Tumor ◽  
Cancer Metastasis ◽  
Histological Grade ◽  
Breast Tumors ◽  
Second Primary ◽  
Primary Tumors ◽  
Second Primary Tumors

e11539 Background: We aimed to investigate the clinical and pathologic characteristics of patients with breast cancer (BC) who had a non-breast primary tumor and treated in our hospital. Methods: We identified BC patients with a second non-breast primary tumor retrospectively in our database. The tumors arising in a sequence by less than 2 months are accepted as synchronous malignancies. We noted clinical and pathological characteristics of breast tumors and analyzed the relapse patterns, the frequency and type of second non-breast primary tumors. Results: A total of 48 patients were identified. Median age was 59 years old. Thirty-four patients were postmenopausal, 41 tumors were IDC, 2 were DCIS only, eight were multiffocal. Two patients had metastatic BC at the time of diagnosis. Ninety-three (n: 26) % patients had breast conserving surgery, 2 had bilateral BC. Twenty-eight patients had node negative disease, 12 had node positive disease and 2 had micrometatatic nodal involvement. Fifty-four % were T1, 31% were T2 tumors. Histological grade was 3 for 14, 2 for 15 and 1 for 7 breast tumors. Forty patients had ER positive disease, 4 had ER/ PR negative disease, 2 tumors were triple negative and 6 tumors were Her-2 positive. Among non-breast second primary tumors; 29 arose after, 11 arose before the diagnosis of BC and 8 arose synchronously with BC. The most common non-breast second primary tumors were as follows: 15% lung cancer, 20% colorectal cancers, 13% ovarian cancer, 10% thyroid cancer, and 8% lymphoma/leukemia. With a median follow up of 76 months, there were 6 relapses; 4 of them were BC relapses. Among these 4 BC relapses, 3 patients had brain metastases and one patient had bone metastasis. There were 4 deaths; 2 were due to BC metastases, one was due to rectal cancer metastasis and the other was due to relapse of sarcoma. Conclusions: Most breast tumors were at early stage and were hormone sensitive. The most common second non-breast primary tumors arising after diagnosis of BC were colorectal, thyroid and lung cancers. The most common second non-breast tumor arising synchronously with BC was lung cancer and the most common second non-breast tumor arising before diagnosis of BC was lymphoma/leukemia.

Sign in / Sign up

Export Citation Format

Share Document